Exhibits a potent RNase activity (PubMed:12244054, PubMed:12527768, PubMed:17150966). Has broad-spectrum antimicrobial activity against many pathogenic microorganisms and remarkably potent activity (lethal dose of 90% < 30 nM) against a vancomycin resistant Enterococcus faecium (PubMed:12244054, PubMed:12527768, PubMed:25075772, PubMed:17150966). Causes loss of bacterial membrane integrity (PubMed:17150966). Probably contributes to urinary tract sterility (PubMed:25075772). Bactericidal activity is independent of RNase activity (PubMed:17150966).
序列
该RNASE7 Recombinant Protein的序列请参考该产品的说明书
来源宿主
E.coli
溶解建议
该RNASE7 Recombinant Protein的溶解建议请参考该产品的说明书
保存建议
该RNASE7 Recombinant Protein的保存建议请参考该产品的说明书
其他
Aviva Systems Biology总部位于加利福尼亚州圣迭戈,在中国北京设有办公室,专注于为研究需求提供多克隆和单克隆抗体、ELISA试剂盒、蛋白质和定制服务。Aviva Systems Biology生产了24,000种经过验证的多克隆抗体,并提供近20,000种ELISA试剂盒,定制实验室服务包括蛋白表达和纯化、抗体开发,以及ELISA的开发、验证和生产。Aviva Systems Biology为与独特物种和靶标相关的研究提供独特工具,研究领域包括转录因子、癌症、心血管、细胞生物学、DNA损伤和修复、表观遗传学、信号转导、细胞分化、干细胞生物学等等。